Karyopharm Therapeutics (KPTI) Total Non-Current Liabilities (2014 - 2026)

Karyopharm Therapeutics (KPTI) has 8 years of Total Non-Current Liabilities data on file, last reported at $390.2 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 12.14% year-over-year to $390.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $390.2 million (up 12.14% YoY) and the FY2025 annual result came in at $390.2 million, up 12.14% from the prior year.
• Total Non-Current Liabilities rose to $390.2 million in Q4 2025, from $292.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $390.2 million in Q4 2025 to a low of $237.2 million in Q2 2021.
• A 5-year average of $302.1 million and a median of $282.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 54.68% — and 2024, when it plunged 34.86%.
• Tracing KPTI's Total Non-Current Liabilities over 5 years: stood at $252.0 million in 2021, then jumped by 48.75% to $374.8 million in 2022, then grew by 0.22% to $375.7 million in 2023, then slipped by 7.36% to $348.0 million in 2024, then rose by 12.14% to $390.2 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $390.2 million (Q4 2025), $292.0 million (Q3 2025), and $270.3 million (Q2 2025), per Business Quant data.